This innovative treatment that efficiently targets HER2 overexpressing cells through multiple methods is being considered for a randomized phase II clinical trial, which creates an opportunity for the treatment of HER2-positive cancer patients [48]. This evidence concerns the gene ERBB2 and cancer.